SG11201808842VA - Heteroaryl substituted pyridines and methods of use - Google Patents
Heteroaryl substituted pyridines and methods of useInfo
- Publication number
- SG11201808842VA SG11201808842VA SG11201808842VA SG11201808842VA SG11201808842VA SG 11201808842V A SG11201808842V A SG 11201808842VA SG 11201808842V A SG11201808842V A SG 11201808842VA SG 11201808842V A SG11201808842V A SG 11201808842VA SG 11201808842V A SG11201808842V A SG 11201808842VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- wittelaan
- generaal
- mechelen
- galapagos
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345315P | 2016-06-03 | 2016-06-03 | |
| PCT/IB2017/053068 WO2017208115A1 (en) | 2016-06-03 | 2017-05-24 | Heteroaryl substituted pyridines and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808842VA true SG11201808842VA (en) | 2018-11-29 |
Family
ID=59014678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808842VA SG11201808842VA (en) | 2016-06-03 | 2017-05-24 | Heteroaryl substituted pyridines and methods of use |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10138227B2 (pt) |
| EP (1) | EP3464282B1 (pt) |
| JP (3) | JP6968094B2 (pt) |
| KR (1) | KR102469995B1 (pt) |
| CN (2) | CN114671864A (pt) |
| AR (2) | AR108672A1 (pt) |
| AU (3) | AU2017273215B2 (pt) |
| BR (1) | BR112018074815A2 (pt) |
| CA (1) | CA3022216A1 (pt) |
| CL (1) | CL2018003323A1 (pt) |
| CO (1) | CO2018012171A2 (pt) |
| CR (1) | CR20180547A (pt) |
| CY (1) | CY1124031T1 (pt) |
| DK (1) | DK3464282T3 (pt) |
| DO (1) | DOP2018000257A (pt) |
| EC (1) | ECSP18094790A (pt) |
| ES (1) | ES2806873T3 (pt) |
| HR (1) | HRP20201068T1 (pt) |
| HU (1) | HUE050248T2 (pt) |
| IL (3) | IL303196A (pt) |
| LT (1) | LT3464282T (pt) |
| MX (2) | MX2018014758A (pt) |
| PE (1) | PE20190511A1 (pt) |
| PH (1) | PH12018502534B1 (pt) |
| PL (1) | PL3464282T3 (pt) |
| PT (1) | PT3464282T (pt) |
| RS (1) | RS60574B1 (pt) |
| RU (2) | RU2021127810A (pt) |
| SG (1) | SG11201808842VA (pt) |
| SI (1) | SI3464282T1 (pt) |
| TW (3) | TWI849782B (pt) |
| UY (1) | UY37272A (pt) |
| WO (1) | WO2017208115A1 (pt) |
| ZA (1) | ZA201808423B (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100921397B1 (ko) * | 2009-02-09 | 2009-10-14 | (주)오엠티 | 인쇄회로기판의 세척장비 및 이를 이용한 세척방법 |
| SG10201913603QA (en) | 2014-10-06 | 2020-02-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| US10793547B2 (en) | 2016-12-09 | 2020-10-06 | Vertex Pharmaceuticals Incorporated | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
| TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3069226A1 (en) | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
| US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| CA3078893A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of cftr modulators |
| JP7245834B2 (ja) | 2017-12-08 | 2023-03-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを作成するためのプロセス |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| PT3752510T (pt) | 2018-02-15 | 2023-03-15 | Vertex Pharma | Macrociclos como moduladores do regulador de condutância de transmembrana da fibrose cística, suas composições farmacêuticas, seu uso no tratamento da fibrose cística e processos para produzi-los |
| US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| IT201900000687A1 (it) * | 2019-01-16 | 2020-07-16 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento della fibrosi cistica |
| EP3747882A1 (en) | 2019-06-03 | 2020-12-09 | AbbVie Overseas S.à r.l. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| WO2021011327A1 (en) | 2019-07-12 | 2021-01-21 | Orphomed, Inc. | Compound for treating cystic fibrosis |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
| BR112022009185A2 (pt) * | 2019-11-12 | 2022-07-26 | Genzyme Corp | Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente |
| AU2021329507A1 (en) | 2020-08-20 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating respiratory diseases characterized by mucus hypersecretion |
| WO2022150174A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| IL309501A (en) | 2021-08-19 | 2024-02-01 | Syngenta Crop Protection Ag | Method for controlling pests resistant to diamide and compounds therefor |
| WO2024056798A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
| WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
| CN116813569B (zh) * | 2023-07-10 | 2024-07-02 | 衡阳市中心医院 | 一种抗癌药中间体的制备方法和抗癌药的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7414037B2 (en) * | 2004-03-30 | 2008-08-19 | The Regents Of The University Of California | Hydrazide-containing CFTR inhibitor compounds and uses thereof |
| EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
| BR122018075478B8 (pt) | 2004-06-24 | 2023-10-31 | Vertex Pharma | moduladores de transportadores de cassete de ligação de atp |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US8283351B2 (en) * | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| ES2548292T3 (es) | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| KR101578235B1 (ko) | 2007-12-10 | 2015-12-16 | 노파르티스 아게 | 유기 화합물 |
| JP5637859B2 (ja) | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| JP5645835B2 (ja) | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｎ−（４−（７−アザビシクロ［２．２．１］ヘプタン−７−イル）−２−（トリフルオロメチル）フェニル）−４−オキソ−５−（トリフルオロメチル）−１，４−ジヒドロキノリン−３−カルボキサミドの固体形態 |
| EA018891B1 (ru) * | 2008-10-23 | 2013-11-29 | Вертекс Фармасьютикалз, Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
| EP2382197B1 (en) | 2008-12-30 | 2016-10-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| US8247436B2 (en) * | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| ES2553771T3 (es) | 2010-10-08 | 2015-12-11 | Nivalis Therapeutics, Inc. | Nuevos compuestos de quinolina sustituidos como inhibidores de la S-nitrosoglutatión reductasa |
| WO2012154880A1 (en) * | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| CN103946221B (zh) * | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| EP2755652B1 (en) * | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| BR112014006535A2 (pt) | 2011-09-20 | 2017-03-28 | Univ North Carolina Chapel Hill | regulação dos canais de sódio através das proteínas plunc |
| AU2014264936B2 (en) | 2013-05-07 | 2018-09-27 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis |
| RU2708690C2 (ru) | 2013-08-08 | 2019-12-11 | Галапагос Нв | Производные тиено[2,3-c]пиранов в качестве cftr модуляторов |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP3116870A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| BR112017009194A2 (pt) | 2014-10-31 | 2017-12-26 | Abbvie Sarl | tetra-hidropiranos substituídos e método de uso |
| PL3212189T3 (pl) | 2014-10-31 | 2021-03-08 | AbbVie Overseas S.à r.l. | Podstawione chromany i sposób użycia |
| CA2981495C (en) * | 2015-03-31 | 2023-09-26 | Vertex Pharmaceuticals (Europe) Limited | Deuterated vx-661 |
| US10047051B2 (en) | 2015-06-02 | 2018-08-14 | Abbvie S.Á.R.L. | Substituted pyridines and method of use |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| CA3001094A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.A.R.L. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| US9890158B2 (en) | 2015-10-09 | 2018-02-13 | Abbvie S.Á.R.L. | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
| BR112018072047A2 (pt) | 2016-04-26 | 2019-02-12 | AbbVie S.à.r.l. | moduladores da proteína reguladora de condutância transmembranar de fibrose cística |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
-
2017
- 2017-05-23 US US15/602,892 patent/US10138227B2/en active Active
- 2017-05-24 MX MX2018014758A patent/MX2018014758A/es unknown
- 2017-05-24 PE PE2018003091A patent/PE20190511A1/es unknown
- 2017-05-24 HU HUE17728272A patent/HUE050248T2/hu unknown
- 2017-05-24 RS RS20200829A patent/RS60574B1/sr unknown
- 2017-05-24 KR KR1020187031861A patent/KR102469995B1/ko active IP Right Grant
- 2017-05-24 CN CN202210433324.9A patent/CN114671864A/zh active Pending
- 2017-05-24 CN CN201780033214.0A patent/CN109311864B/zh active Active
- 2017-05-24 DK DK17728272.0T patent/DK3464282T3/da active
- 2017-05-24 SG SG11201808842VA patent/SG11201808842VA/en unknown
- 2017-05-24 PT PT177282720T patent/PT3464282T/pt unknown
- 2017-05-24 CA CA3022216A patent/CA3022216A1/en active Pending
- 2017-05-24 AU AU2017273215A patent/AU2017273215B2/en active Active
- 2017-05-24 BR BR112018074815-3A patent/BR112018074815A2/pt active Search and Examination
- 2017-05-24 RU RU2021127810A patent/RU2021127810A/ru unknown
- 2017-05-24 PL PL17728272T patent/PL3464282T3/pl unknown
- 2017-05-24 ES ES17728272T patent/ES2806873T3/es active Active
- 2017-05-24 LT LTEP17728272.0T patent/LT3464282T/lt unknown
- 2017-05-24 JP JP2018552704A patent/JP6968094B2/ja active Active
- 2017-05-24 WO PCT/IB2017/053068 patent/WO2017208115A1/en unknown
- 2017-05-24 IL IL303196A patent/IL303196A/en unknown
- 2017-05-24 RU RU2018138707A patent/RU2756743C2/ru active
- 2017-05-24 SI SI201730320T patent/SI3464282T1/sl unknown
- 2017-05-24 IL IL288243A patent/IL288243B2/en unknown
- 2017-05-24 EP EP17728272.0A patent/EP3464282B1/en active Active
- 2017-05-24 CR CR20180547A patent/CR20180547A/es unknown
- 2017-06-02 AR ARP170101516A patent/AR108672A1/es active IP Right Grant
- 2017-06-02 UY UY0001037272A patent/UY37272A/es unknown
- 2017-06-03 TW TW112108367A patent/TWI849782B/zh active
- 2017-06-03 TW TW110149319A patent/TWI797926B/zh active
- 2017-06-03 TW TW106118418A patent/TWI752961B/zh active
-
2018
- 2018-10-16 IL IL262415A patent/IL262415B/en unknown
- 2018-10-19 US US16/165,662 patent/US10604515B2/en active Active
- 2018-11-13 CO CONC2018/0012171A patent/CO2018012171A2/es unknown
- 2018-11-22 CL CL2018003323A patent/CL2018003323A1/es unknown
- 2018-11-26 DO DO2018000257A patent/DOP2018000257A/es unknown
- 2018-11-29 MX MX2021009322A patent/MX2021009322A/es unknown
- 2018-11-29 PH PH12018502534A patent/PH12018502534B1/en unknown
- 2018-12-13 ZA ZA2018/08423A patent/ZA201808423B/en unknown
- 2018-12-26 EC ECSENADI201894790A patent/ECSP18094790A/es unknown
-
2020
- 2020-07-07 HR HRP20201068TT patent/HRP20201068T1/hr unknown
- 2020-07-14 CY CY20201100646T patent/CY1124031T1/el unknown
-
2021
- 2021-10-25 JP JP2021173679A patent/JP7392211B2/ja active Active
- 2021-12-07 AU AU2021282409A patent/AU2021282409B2/en not_active Expired - Fee Related
-
2022
- 2022-02-18 AR ARP220100344A patent/AR124916A2/es unknown
-
2023
- 2023-03-27 JP JP2023049450A patent/JP2023172889A/ja active Pending
-
2024
- 2024-04-16 AU AU2024202468A patent/AU2024202468A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808842VA (en) | Heteroaryl substituted pyridines and methods of use | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201903348UA (en) | Therapeutic compounds and methods of use thereof | |
| SG11201811345TA (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
| SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors | |
| SG11201908568XA (en) | Therapeutic compounds and methods | |
| SG11201903091VA (en) | Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors |